MERCK
Merck, a leading science and technology company, today announced a mutual decision with GSK to terminate their agreement on bintrafusp alfa, effective September 30, 2021.
The decision is based on the clinical trial data generated to date, most notably the previously reported results from the INTR@PID Lung 037 study, which did not replicate the encouraging data observed in earlier studies. Based on the data generated during the agreement, no milestone payments were made by GSK and no future milestone obligations remain.
The INTR@PID clinical program sought to validate the potential of the novel mechanism of simultaneously blocking TGF-ß and PD-L1, with the ambition to improve outcomes for patients with difficult-to-treat cancers. Given the extent of the clinical program, Merck will deepen its scientific leadership in the field and interrogate the data leveraging the power of advanced analytics. The important insights this program has yielded about the biology of TGF-β will inform the collective understanding of this pathway.
Merck is a science-led organization dedicated to delivering transformative medicines with the goal of making a meaningful difference in the lives of people affected by cancer. Our oncology research efforts, comprised of 10 ongoing development programs, aim to leverage our synergistic portfolio in oncogenic pathways, immuno-oncology, and DNA Damage Response (DDR) to tackle challenging tumor types in gastrointestinal, genitourinary, and head and neck and thoracic cancers. Learn more at https://www.merckgrouponcology.com .
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
About Merck
Merck, a leading science and technology company, operates across healthcare, life science and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck generated sales of € 17.5 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005596/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Energy Vault Secures Swiss Market Entry with Signed B-VAULT™ Deployment Contracts for Schindler and Energie Wettingen Projects, Launch of FlexGrid Product for Urban and Utility Applications4.12.2025 15:20:00 CET | Press release
Energy Vault signs two B-VAULT™ contracts in the Swiss market for projects with Schindler Aufzüge AG and Energie Wettingen, marking the launch of Energy Vault’s B-Vault™ FlexGrid program designed for commercial and industrial (C&I) customersSwitzerland is a cornerstone of Energy Vault’s European strategy, with the company moving decisively to expand its presence with multiple projects per year as part of a broader European growth strategyIntegration with CKW’s Flexpool flexibility market set to enable participation in frequency regulation, voltage control, and reactive power marketsThe Schindler FlexGrid-enabled B-VAULT system is operating and qualified by Swissgrid Energy Vault Holdings, Inc. (NYSE: NRGV) ("Energy Vault" or the "Company"), a global leader in grid-scale energy storage solutions, today announced its formal entry into the Swiss market with the launch of FlexGrid, a product designed for C&I customers based on a new configuration of its B-VAULT battery energy storage syste
MSCI Launches Breakthrough Index Integrating Public Markets and Private Equity4.12.2025 15:00:00 CET | Press release
Innovative index is designed to provide a broad and daily view of the global equity opportunity MSCI Inc. (NYSE: MSCI) launched the MSCI All Country Public + Private Equity Index,an innovative daily index that combines public markets and a broad private equity view within a single, coherent framework. The launch marks a major shift in how investors can assess total equity exposures and measure performance across their portfolio. With private markets increasingly integrated into investment portfolios, private equity is becoming a core component of total portfolio allocation, contributing to diversification, long-term return potential and exposure to segments of the economy not captured by public markets. Reflecting the evolving structure of investor portfolios, this index sets a new standard for tracking global equity performance across public and private markets. The index combines the flagship MSCI ACWI IMI, which represents the performance of the full opportunity set of publicly list
University of Maryland Launches Innovative Clinician Training Program in Ketogenic Metabolic Therapy for Mental Health4.12.2025 15:00:00 CET | Press release
Funding from Baszucki Group fuels program for healthcare professionals to learn by doing. Baszucki Group today announced a partnership with University of Maryland School of Medicine for an innovative training initiative that will build capacity for delivering ketogenic metabolic therapy in mental health care. The program, titled “LIVE IT~LAUNCH IT: Learning How to Implement and Use a Ketogenic Diet to Improve Mental Health in Your Patients For Health Care Workers” is led by Deanna Kelly, PharmD, BCPP, the Dr. William and Carol Carpenter Professor in Psychiatry for Mental Illness Research and Director of the Maryland Psychiatric Research Center at the University of Maryland School of Medicine. This initiative aims to educate and empower practitioners by guiding them in adopting the intervention themselves. The aim is to prepare a variety of healthcare professionals to safely and confidently incorporate this promising personalized metabolic treatment framework in both clinical and resear
I-care Group Continues Global Expansion with a European Training Arm4.12.2025 15:00:00 CET | Press release
Technical Associates of Europe builds on 60+ years of training excellence I-care Group, the global leader in predictive maintenance and reliability solutions, announces the launch of Technical Associates of Europe (TAE), a new independent and certifying training organization headquartered in Mons, Belgium. This strategic initiative strengthens I-care’s global development and extends its professional training offerings in maintenance, reliability, lubrication and predictive-maintenance technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204628319/en/ Building on the heritage of Technical Associates of Charlotte (TAC) — a U.S. training organization founded in 1961 and acquired by I-care Group in 2023 —Technical Associates of Europe represents a major expansion of I-care’s training ecosystem. “Technical Associates of Europe marks an important milestone in I-care’s journey,” said Fabrice Brion, CEO of I-care Group. “
Cross-Border Private Credit Set to Surge, But Operational Complexity Threatens Momentum, CSC Finds4.12.2025 14:30:00 CET | Press release
79% of GPs expect cross-border private credit deals to grow over the next three years, with more than half forecasting rapid acceleration40% of LPs rejected private credit investment opportunities last year due to reporting or operational concerns92% of LPs say specialist outsourcing enhances transparency Cross-border private credit transactions are poised for strong growth, yet operational complexity is emerging as a critical hurdle. According to CSC, the leading provider of business administration and compliance solutions, an overwhelming 92% of limited partners (LPs) express concern over the complexity of these deals. Published in CSC’s latest report, Private Credit 2025: Global Strategies for a $1.5 Trillion Market, the findings highlight a growing disconnect between investors and fund managers as private credit continues its rapid international expansion. 1 While both LPs and general partners (GPs) remain optimistic about the growth of cross-border private credit, they diverge sha
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom